Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 177Lu-NNS309 |
Synonyms | |
Therapy Description |
177Lu-NNS309 is a radioconjugate comprising a moiety that binds an undisclosed target conjugated to the beta-emitting radionuclide Lu177, which potentially induces cytotoxicity in tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
177Lu-NNS309 | Lutetium Lu 177 NNS309|[177Lu]Lu-NNS309 | 177Lu-NNS309 is a radioconjugate comprising a moiety that binds an undisclosed target conjugated to the beta-emitting radionuclide Lu177, which potentially induces cytotoxicity in tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06562192 | Phase I | 177Lu-NNS309 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Recruiting | USA | ISR | CHE | CAN | 0 |